Hemab Therapeutics Holdings, Inc. (COAG)

COAG Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Income Operating Income Growth	-87.19	-70.12	-50.38
Net Income Net Income Growth	-83.24	-63.91	-48.71
Earnings Per Share EPS Growth	-10.06	-67.56	-51.49
EPS Growth	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Cash & Investments Cash & Investments Growth	457.46	185.49	88.33
Total Debt Total Debt Growth	1.03	1.27	1.89
Net Cash (Debt) Net Cash Growth	456.43	184.22	86.43
Net Cash Growth	-	113.13%	-
Net Cash Per Share Net Cash Per Share Growth	55.14	194.73	91.37

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Cash Flow Operating Cash Flow Growth	-77.33	-61.48	-45.59
Capital Expenditures CapEx Growth	-0.14	-0.02	-0.28
Free Cash Flow Free Cash Flow Growth	-77.47	-61.49	-45.87
Free Cash Flow Growth	-	-	-

Data Source: S&P Global Market Intelligence Last updated: May 21, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 28, 2026

Data Sources Report a data error